A preclinical study of levosimendan, which was conducted by Hansen et al earlier in the month has recorded positive results. According to Tenax Therapeutics Inc (NASDAQ:TENX), Dr. Hansen and colleagues gave the study all the efforts and attention it required as they evaluated the effects of levosimendan in an experimental model of right heart failure. From the results, the team concluded that chronic administration of levosimendan improved right heart function.
Expressing his contentment in the results, acting CEO of Tenax Therapeutics, Michael Jebsen said, The promising findings reported in the scientific literature provide additional support to our hypothesis that levosimendan has the potential to offer significant benefits in the treatment of Pulmonary Hypertension associated with Heart Failure.”
Levosimendan will be an alternative treatment to other approved therapies
There are hundreds of patients living with Pulmonary Hypertension associated, which more often than not is associated with Heart Failure and Preserved Ejection Fraction (PH-HFpEF). A majority of them have sought help from the approved therapies but they have not been successful. Thus levosimendan’s unique mechanisms of action are expected to provide an alternative therapy.
Apparently, this is not the first time that the results of such a study are being published having been carried out by Dr. Hansen and colleagues. In October 2017 the team published similar findings in Journal of Cardiovascular Pharmacology. On the other hand, similar clinical trials have been conducted by Kleber et al and Jiang et al in 2009 and 2017 respectively. Each of the studies outlined the benefits levosimendan would offer patients with pulmonary hypertension.
Tenax Therapeutics’ focus is on licensing, development, and commercialization of drugs
The pharmaceutical company has a big vision, which involves addressing conditions with high unmet medical need. It is also worth mentioning that the company’s scientific team has recognized experts who have a global recognition. With all its strengths, it obtained the North American rights from Phyxius Pharma and it can now develop and commercialize levosimendan.
Meanwhile, the initial development of levosimendan was focusing on hospitalized patients with acutely decompensated heart failure. The treatment has an approval in over 60 countries but apparently, it is not available in the US markets.